179 related articles for article (PubMed ID: 23632404)
1. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial.
Katayama BY; Bonini-Filho MA; Messias AM; Paula JS; Martin LF; Costa R; Jorge R
J Glaucoma; 2014 Sep; 23(7):461-3. PubMed ID: 23632404
[TBL] [Abstract][Full Text] [Related]
2. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
3. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
[TBL] [Abstract][Full Text] [Related]
4. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
5. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.
Soheilian M; Karimi S; Montahae T; Nikkhah H; Mosavi SA
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1705-1712. PubMed ID: 28616715
[TBL] [Abstract][Full Text] [Related]
7. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration.
Ichiyama Y; Sawada T; Kakinoki M; Sawada O; Nakashima T; Saishin Y; Kawamura H; Ohji M
Ophthalmic Res; 2014; 52(4):234-8. PubMed ID: 25401265
[TBL] [Abstract][Full Text] [Related]
8. Paracentesis before intravitreal injection of bevacizumab.
Tsui YP; Chiang CC; Tsai YY
Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
[No Abstract] [Full Text] [Related]
9. [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
El Chehab H; Le Corre A; Giraud JM; Ract-Madoux G; Swalduz B; Dot C
J Fr Ophtalmol; 2012 Oct; 35(8):614-21. PubMed ID: 22832030
[TBL] [Abstract][Full Text] [Related]
10. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection.
El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C
Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177
[TBL] [Abstract][Full Text] [Related]
11. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension.
Kim GN; Han YS; Chung IY; Seo SW; Park JM; Yoo JM
Semin Ophthalmol; 2013 Mar; 28(2):61-7. PubMed ID: 23448557
[TBL] [Abstract][Full Text] [Related]
12. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
Murray CD; Wood D; Allgar V; Walters G; Gale RP
Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
[TBL] [Abstract][Full Text] [Related]
14. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
15. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
16. [Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs].
Andreeva YS; Alkharki L; Shelankova AV; Budzinskaya MV
Vestn Oftalmol; 2024; 140(2. Vyp. 2):73-79. PubMed ID: 38739134
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dorzolamide/timolol versus brimonidine/timolol fixed combination therapy in the management of steroid-induced ocular hypertension.
Seymenoğlu G; Baser EF; Öztürk B; Gülhan C
J Glaucoma; 2015 Feb; 24(2):111-6. PubMed ID: 23807349
[TBL] [Abstract][Full Text] [Related]
18. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
19. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
20. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study.
Knip MM; Välimäki J
Acta Ophthalmol; 2012 May; 90(3):254-8. PubMed ID: 20456259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
